Related references
Note: Only part of the references are listed.Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD-Disease Outcome and Response to Therapy
Bram Verstockt et al.
JOURNAL OF CROHNS & COLITIS (2021)
Real-World Effectiveness and Safety of Ustekinumab for Ulcerative Colitis From 2 Tertiary IBD Centers in the United States
Simon J. Hong et al.
CROHNS & COLITIS 360 (2021)
Real-World Effectiveness and Safety of Ustekinumab for Ulcerative Colitis From 2 Tertiary IBD Centers in the United States
Simon J. Hong et al.
CROHNS & COLITIS 360 (2021)
Leukocytoclastic Vasculitis Related to Ustekinumab in a Crohn's Disease Patient: First Case Report and Literature Review
Pedro Costa-Moreira et al.
JOURNAL OF CROHNS & COLITIS (2020)
Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2020)
P099 LEUKOCYTOCLASTIC VASCULITIS AFTER USTEKINUMAB INDUCTION IN CROHN'S DISEASE: A CASE SERIES AND SYSTEMATIC REVIEW
Rishika Chugh et al.
GASTROENTEROLOGY (2020)
DOP65 Mirikizumab regulates genes involved in anti-TNF resistance and ulcerative colitis disease activity
B Steere et al.
Journal of Crohns & Colitis (2020)
DOP56 Ustekinumab maintained clinically meaningful improvement in health-related quality of life in patients with moderate to severe ulcerative colitis: Results from the UNIFI long-term extension
W J Sandborn et al.
Journal of Crohns & Colitis (2020)
P719 Effectiveness and safety of ustekinumab induction therapy in ulcerative colitis: A GETAID real-world cohort study
A Amiot et al.
Journal of Crohns & Colitis (2020)
P687 Early and sustained improvement in stool frequency and rectal bleeding following 52 weeks of mirikizumab treatment
G R D’Haens et al.
Journal of Crohns & Colitis (2020)
OP28 Gene expression (GE) values in a phase 2 trial of mirikizumab in ulcerative colitis (UC) correlate better with histopathology (HP) than endoscopy (EN) and Mayo scores
B Steere et al.
Journal of Crohns & Colitis (2020)
P434 Effectiveness and safety of ustekinumab in ulcerative colitis: real-world evidence from Eneida Registry
M Chaparro et al.
Journal of Crohns & Colitis (2020)
P565 Efficacy and safety of long-term treatment with ustekinumab in moderate–severe ulcerative colitis patients with delayed response to ustekinumab induction: Results from UNIFI 2-year long-term extension
B E Sands et al.
Journal of Crohns & Colitis (2020)
P712 Association of histologic-endoscopic mucosal healing after ustekinumab induction or maintenance therapy with 2-year outcomes in the UNIFI Phase 3 study in ulcerative colitis
K Li et al.
Journal of Crohns & Colitis (2020)
P633 Sustained reduction of IL-23-related cytokines IL-17A and IL-22 in a phase 2 study of mirikizumab in the treatment of patients with moderately-to-severely active ulcerative colitis through week 52
G R D’Haens et al.
Journal of Crohns & Colitis (2020)
Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial
Christopher T Ritchlin et al.
LANCET (2020)
Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study
Desiree van der Heijde et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Tu1849 HISTOLOGIC REMISSION AND MUCOSAL HEALING IN A PHASE 2 STUDY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Rish Pai et al.
GASTROENTEROLOGY (2020)
Tu1887 IMPACT OF MIRIKIZUMAB TREATMENT ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ULCERATIVE COLITIS: A PHASE 2 STUDY ANALYSIS USING THE SF-36 V2 STANDARD
Gary R. Lichtenstein et al.
GASTROENTEROLOGY (2020)
Tu1886 DOSE ADJUSTMENT IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: RESULTS FROM THE UNIFI MAINTENANCE STUDY LONG-TERM EXTENSION
Bruce E. Sands et al.
GASTROENTEROLOGY (2020)
Sa1893 PRIOR IMMUNOGENICITY TO ANTI-TNF BIOLOGICS IS NOT ASSOCIATED WITH INCREASED ANTI-DRUG ANTIBODIES TO VEDOLIZUMAB OR USTEKINUMAB
Nicholas J. Costable et al.
GASTROENTEROLOGY (2020)
Sa1827 PREGNANCY OUTCOMES IN WOMEN WITH PSORIASIS, PSORIATIC ARTHRITIS, CROHN'S DISEASE AND ULCERATIVE COLITIS TREATED WITH USTEKINUMAB
Sheri Volger et al.
GASTROENTEROLOGY (2020)
Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials
Mark C. Genovese et al.
RHEUMATOLOGY (2020)
Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study
Andrew Blauvelt et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
S0872 Healthcare Cost Offsets From Reductions in Ulcerative Colitis-Related Hospitalizations and Surgeries in Patients Treated With Ustekinumab in the UNIFI Study
Zhijie Ding et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2020)
S2261 Combining Cyclosporine With Ustekinumab in Acute Severe Ulcerative Colitis: Report of 2 Cases
Seth R. Shaffer et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2020)
S2269 Efficacy of Intravenous Ustekinumab as Induction Therapy for Patients Hospitalized With Severe Inflammatory Bowel Disease: A Case Series
Alexander Hooper et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2020)
S0779 Effect of Ustekinumab Maintenance Therapy on Stool Frequency and Rectal Bleeding Through 2 Years in the UNIFI Phase 3 Study in Ulcerative Colitis
Maria T. Abreu et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2020)
S0682 Absence of Bowel Urgency Is Associated With Significantly Improved Inflammatory Bowel Disease Related Quality of Life in a Phase 2 Trial of Mirikizumab in Patients With Ulcerative Colitis
Marla C. Dubinsky et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2020)
S0683 Absence of Bowel Urgency Is Associated With Improvements in Clinical Outcomes in Patients With Ulcerative Colitis Receiving Mirikizumab
Marla C. Dubinsky et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2020)
S0845 Pharmacokinetics and Immunogenicity of Maintenance Therapy With Ustekinumab: 2-Year Results From the UNIFI Long-Term Extension Study
Omoniyi Adedokun et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2020)
Gut microbiome composition and risk factors in a large cross-sectional IBS cohort
Melissa Agnello et al.
BMJ OPEN GASTROENTEROLOGY (2020)
Incidence and Risk of Inflammatory Bowel Disease in Patients with Psoriasis-A Nationwide 20-Year Cohort Study
Alexander Egeberg et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2019)
Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials
Stefan Schreiber et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Microbiota Sensing by Mincle-Syk Axis in Dendritic Cells Regulates Interleukin-17 and-22 Production and Promotes Intestinal Barrier Integrity
Maria Martinez-Lopez et al.
IMMUNITY (2019)
Gut Microbiome in Psoriasis is Perturbed Differently During Secukinumab and Ustekinumab Therapy and Associated with Response to Treatment
Nai-Lun Yeh et al.
CLINICAL DRUG INVESTIGATION (2019)
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
B. E. Sands et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
IL-23 in inflammatory bowel diseases and colon cancer
Markus F. Neurath
CYTOKINE & GROWTH FACTOR REVIEWS (2019)
IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting
Alexander R. Moschen et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2019)
Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab
D. Laharie et al.
GUT (2018)
Can IL-23 be a good target for ulcerative colitis?
Mariangela Allocca et al.
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2018)
Anti-IL-23 receptor monoclonal antibody prevents CD4+ T cell-mediated colitis in association with decreased systemic Th1 and Th17 responses
Emiko Imamura et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2018)
Importance of TLR9-IL23-1L17 axis in inflammatory bowel disease development: Gene expression profiling study
Sanja Dragasevic et al.
CLINICAL IMMUNOLOGY (2018)
The Gut Microbiota in the Pathogenesis and Therapeutics of Inflammatory Bowel Disease
Tao Zuo et al.
FRONTIERS IN MICROBIOLOGY (2018)
Evaluation of interleukin 23 (IL-23) as a non-invasive test of disease severity in patients with ulcerative colitis
Tarek Youssef et al.
ARAB JOURNAL OF GASTROENTEROLOGY (2018)
Association of Psoriasis With Inflammatory Bowel Disease A Systematic Review and Meta-analysis
Yun Fu et al.
JAMA DERMATOLOGY (2018)
Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis
S. Bonovas et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
IL-23R mutation is associated with ulcerative colitis: A systemic review and meta-analysis
Ling-Long Peng et al.
ONCOTARGET (2017)
Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a Study
Bruce E. Sands et al.
GASTROENTEROLOGY (2017)
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management
Marcus Harbord et al.
JOURNAL OF CROHNS & COLITIS (2017)
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders
Fernando Magro et al.
JOURNAL OF CROHNS & COLITIS (2017)
Meta-Analysis of Risk Association Between Interleukin-17A and F Gene Polymorphisms and Inflammatory Diseases
Ebrahim Eskandari-Nasab et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2017)
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
IL23R single nucleotide polymorphisms could be either beneficial or harmful in ulcerative colitis
Sarah Fischer et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2017)
CD11c+ monocyte/macrophages promote chronic Helicobacter hepaticus-induced intestinal inflammation through the production of IL-23
I. C. Arnold et al.
MUCOSAL IMMUNOLOGY (2016)
Intestinal Interleukin-17 Receptor Signaling Mediates Reciprocal Control of the Gut Microbiota and Autoimmune Inflammation
Pawan Kumar et al.
IMMUNITY (2016)
mTOR Mediates IL-23 Induction of Neutrophil IL-17 and IL-22 Production
Feidi Chen et al.
JOURNAL OF IMMUNOLOGY (2016)
IL-17 in Chronic Inflammation: From Discovery to Targeting
Audrey Beringer et al.
TRENDS IN MOLECULAR MEDICINE (2016)
The IL-23-IL-17 axis in inflammatory arthritis
Erik Lubberts
NATURE REVIEWS RHEUMATOLOGY (2015)
The epidemiology of extra-articular manifestations in ankylosing spondylitis: a population-based matched cohort study
Carmen Stolwijk et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Biological Agents for Moderately to Severely Active Ulcerative Colitis A Systematic Review and Network Meta-analysis
Silvio Danese et al.
ANNALS OF INTERNAL MEDICINE (2014)
Role of the Microbiota in Immunity and Inflammation
Yasmine Belkaid et al.
CELL (2014)
Involvement of IL-23 in enteropathic arthritis patients with inflammatory bowel disease: preliminary results
Tamer A. Gheita et al.
CLINICAL RHEUMATOLOGY (2014)
Interleukin-17 SNPs and serum levels increase ulcerative colitis risk: A meta-analysis
Juan Li et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing
Sarah L. Gaffen et al.
NATURE REVIEWS IMMUNOLOGY (2014)
Influence of IL17A polymorphisms (rs2275913 and rs3748067) on the susceptibility to ulcerative colitis
Ranji Hayashi et al.
CLINICAL AND EXPERIMENTAL MEDICINE (2013)
Work disability in inflammatory bowel disease patients 10 years after disease onset: results from the IBSEN Study
Marte Lie Hoivik et al.
GUT (2013)
Recent advances in inflammatory bowel disease: mucosal immune cells in intestinal inflammation
M. Zaeem Cader et al.
GUT (2013)
Genetic polymorphisms of interleukin 17A and interleukin 17F and their association with inflammatory bowel disease in a Chinese Han population
Xiaofei Zhang et al.
INFLAMMATION RESEARCH (2013)
Serum IL-17A in Newly Diagnosed Treatment-Naive Patients with Ulcerative Colitis Reflects Clinical Disease Severity and Predicts the Course of Disease
Lena Ohman et al.
INFLAMMATORY BOWEL DISEASES (2013)
IL-23/IL-17A Axis Correlates with the Nitric Oxide Pathway in Inflammatory Bowel Disease: Immunomodulatory Effect of Retinoic Acid
Hayet Rafa et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2013)
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Brian G. Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Differential Interleukin-10 (IL-10) and IL-23 Production by Human Blood Monocytes and Dendritic Cells in Response to Commensal Enteric Bacteria
Jennifer Manuzak et al.
CLINICAL AND VACCINE IMMUNOLOGY (2012)
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial
Wolfgang Hueber et al.
GUT (2012)
Ulcerative colitis as a progressive disease: The forgotten evidence
Joana Torres et al.
INFLAMMATORY BOWEL DISEASES (2012)
Review of the disease course among adult ulcerative colitis population-based longitudinal cohorts
Fernando Magro et al.
INFLAMMATORY BOWEL DISEASES (2012)
Cutting Edge: Regulation of Intestinal Inflammation and Barrier Function by IL-17C
Joseph M. Reynolds et al.
JOURNAL OF IMMUNOLOGY (2012)
Toll-Like Receptor 5 Engagement Induces Interleukin-17C Expression in Intestinal Epithelial Cells
Eunok Im et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2012)
Opposing consequences of IL-23 signaling mediated by innate and adaptive cells in chemically induced colitis in mice
J. H. Cox et al.
MUCOSAL IMMUNOLOGY (2012)
Epidemiology and Natural History of Inflammatory Bowel Diseases
Jacques Cosnes et al.
GASTROENTEROLOGY (2011)
Genetic polymorphisms of IL-23R and IL-17A and novel insights into their associations with inflammatory bowel disease
Seung Won Kim et al.
GUT (2011)
Chronic Mucocutaneous Candidiasis in Humans with Inborn Errors of Interleukin-17 Immunity
Anne Puel et al.
SCIENCE (2011)
The increased mucosal mRNA expressions of complement C3 and interleukin-17 in inflammatory bowel disease
T. Sugihara et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2010)
Induction of Intestinal Th17 Cells by Segmented Filamentous Bacteria
Ivaylo I. Ivanov et al.
CELL (2009)
ROR gamma-Expressing Th17 Cells Induce Murine Chronic Intestinal Inflammation via Redundant Effects of IL-17A and IL-17F
Moritz Leppkes et al.
GASTROENTEROLOGY (2009)
Differential Roles of Interleukin-17A and-17F in Host Defense against Mucoepithelial Bacterial Infection and Allergic Responses
Harumichi Ishigame et al.
IMMUNITY (2009)
Th17 Cytokines Stimulate CCL20 Expression in Keratinocytes In Vitro and In Vivo: Implications for Psoriasis Pathogenesis
Erin G. Harper et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2009)
ROR gamma t and commensal microflora are required for the differentiation of mucosal interleukin 22-producing NKp46(+) cells
Stephanie L. Sanos et al.
NATURE IMMUNOLOGY (2009)
A protective function for interleukin 17A in T cell-mediated intestinal inflammation
William O'Connor et al.
NATURE IMMUNOLOGY (2009)
The gut microbiota shapes intestinal immune responses during health and disease
June L. Round et al.
NATURE REVIEWS IMMUNOLOGY (2009)
Specific Microbiota Direct the Differentiation of IL-17-Producing T-Helper Cells in the Mucosa of the Small Intestine
Ivaylo I. Ivanov et al.
CELL HOST & MICROBE (2008)
A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease
William J. Sandborn et al.
GASTROENTEROLOGY (2008)
Role of the novel th17 cytokine IL-17F in inflammatory bowel disease (IBD):: Upregulated colonic IL-17F expression in active Crohn's disease and analysis of the IL17F p.Hisl6lArg polymorphism in IBD
Julia Seiderer et al.
INFLAMMATORY BOWEL DISEASES (2008)
Regulation of inflammatory responses by IL-17F
Xuexian O. Yang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
Differential regulation of interleukin 12 and interleukin 23 production in human dendritic cells
Franca Gerosa et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
IL-23 and Th17 cytokines in intestinal homeostasis
K. J. Maloy et al.
MUCOSAL IMMUNOLOGY (2008)
A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells
Ken Cadwell et al.
NATURE (2008)
The influence of polymorphisms of interleukin-17A and interleukin-17F genes on the susceptibility to ulcerative colitis
Tomiyasu Arisawa et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2008)
Blocking of IL-6 signaling pathway prevents CD4+ T cell-mediated colitis in a Th17-independent manner
Daisuke Noguchi et al.
INTERNATIONAL IMMUNOLOGY (2007)
Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis
Yan Zheng et al.
NATURE (2007)
The IL-23/Th17axis:: therapeutic targets for autoimmune inflammation
Kristine Kikly et al.
CURRENT OPINION IN IMMUNOLOGY (2006)
A genome-wide association study identifies IL23R as an inflammatory bowel disease gene
Richard H. Duerr et al.
SCIENCE (2006)
IL-23 plays a key role in Helicobacter hepaticus-induced T cell-dependent colitis
Marika C. Kullberg et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Cutting edge: IL-23 cross-regulates IL-12 production in T cell-dependent experimental colitis
Christoph Becker et al.
JOURNAL OF IMMUNOLOGY (2006)
Symbiotic bacteria direct expression of an intestinal bactericidal lectin
Heather L. Cash et al.
SCIENCE (2006)
Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology
Holm H. Uhlig et al.
IMMUNITY (2006)
Critical role of IL-17 receptor signaling in acute TNBS-induced colitis
Z Zhang et al.
INFLAMMATORY BOWEL DISEASES (2006)
IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6
D Yen et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Infliximab as rescue therapy in severe to moderately severe ulcerative colitis:: A randomized, placebo-controlled study
G Järnerot et al.
GASTROENTEROLOGY (2005)
NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses
T Watanabe et al.
NATURE IMMUNOLOGY (2004)
Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice
A Ogawa et al.
CLINICAL IMMUNOLOGY (2004)
Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain
DJ Cua et al.
NATURE (2003)
Increased expression of interleukin 17 in inflammatory bowel disease
S Fujino et al.
GUT (2003)
Cutting edge: IL-17F, a novel cytokine selectively expressed in activated T cells and monocytes, regulates angiogenesis and endothelial cell cytokine production
T Starnes et al.
JOURNAL OF IMMUNOLOGY (2001)
Claudins regulate the intestinal barrier in response to immune mediators
T Kinugasa et al.
GASTROENTEROLOGY (2000)
Cloning and characterization of IL-17B and IL-17C, two new members of the IL-17 cytokine family
HZ Li et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Share Paper
